Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Forecast 2026: Where the Industry Is Headed

Uncover key drivers, emerging technologies, and competitive movements shaping the asthma and chronic obstructive pulmonary disease (copd) drugs market from 2026–2035 with trusted insights from The Business Research Company

What was the valuation of the Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market in 2026, and what figure is it projected to hit by 2030?

The asthma and chronic obstructive pulmonary disease (copd) drugs market size has seen significant expansion in recent years. This market is anticipated to expand from $35.66 billion in 2025 to $39.07 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.6%. The historical increase can be attributed to factors such as rising smoking prevalence, urban air pollution, the provision of hospital-based respiratory care, the adoption of inhaler technology, and an increase in asthma diagnoses.

The asthma and chronic obstructive pulmonary disease (copd) drugs market size is anticipated to undergo significant expansion in the upcoming years, projected to reach $55.67 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 9.3%. This expected growth is primarily fueled by innovations in biologic drugs, an aging global population, worsening air quality, the evolution of personalized respiratory medicine, and advancements in homecare respiratory solutions. Prominent trends within this forecast period encompass an increased reliance on combination inhaler therapies, the wider adoption of long-acting bronchodilators, an expansion of biologic therapies for severe asthma, a transition towards managing respiratory conditions in home settings, and a growing demand for generic inhalation drugs.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24472&type=smp

Which Drivers Are Affecting Market Participation In The Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market?

The rising occurrence of smoking is projected to fuel the expansion of the asthma and COPD drugs market in the future. Smoking describes the practice of using tobacco items through smoke inhalation, potentially resulting in severe health conditions like lung cancer and heart disease. This rising prevalence of smoking is largely influenced by social factors, including peer pressure, societal customs, and surroundings that motivate individuals to begin and persist with smoking. Medications for asthma and chronic obstructive pulmonary disease (COPD) work to lessen the respiratory harm from smoking through reducing inflammation, relaxing airway muscles, and improving air circulation, thus easing symptoms and boosting lung function. For example, a 2024 study by the European Respiratory Society’s (ERS), a Switzerland-based non-profit organization, on youth smoking trends revealed a significant jump in smoking rates, increasing from 22.5% of respondents in 2022 to 40.1% in 2024. Consequently, the growing incidence of smoking is boosting the expansion of the asthma and COPD drugs market.

What Segment Categories Are Covered In The Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market?

The asthma and chronic obstructive pulmonary disease (copd) drugs market covered in this report is segmented –

1) By Drug Class: Bronchodilators, Corticosteroids, Combination Drugs, Leukotriene Modifiers

2) By Route Of Administration: Inhalation, Oral, Injection, Other Route Of Administrations

3) By Patient Group: Adult, Pediatric, Geriatric

4) By Application: Asthma, Chronic Obstructive Pulmonary Disease

5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Drug Stores

Subsegments:

1) By Bronchodilators: Short-Acting Beta-2 Agonists (SABA), Long-Acting Beta-2 Agonists (LABA), Anticholinergics, Long-Acting Muscarinic Antagonists, Methylxanthines

2) By Corticosteroids: Inhaled Corticosteroids (ICS), Oral Corticosteroids, Intravenous Corticosteroids

3) By Combination Drugs: Long-Acting Beta-Agonist + Inhaled Corticosteroid, Long-Acting Beta-Agonist + Long-Acting Muscarinic Antagonist, Long-Acting Beta-Agonist + Long-Acting Muscarinic Antagonist + Inhaled Corticosteroid

4) By Leukotriene Modifiers: Leukotriene Receptor Antagonists, Leukotriene Synthesis Inhibitors

What Trends Are Driving The Growth Trajectory Of The Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market?

Leading companies active in the asthma and chronic obstructive pulmonary disease (COPD) drugs market are concentrating on integrating innovative drug-combination therapies, such as short-acting beta-agonist (SABA) and inhaled corticosteroid (ICS) rescue inhalers. This focus aims to amplify benefits like preventing severe asthma attacks, improving inflammation control, and supporting more effective overall disease management. A SABA–ICS rescue inhaler combines a short-acting beta-agonist, which promptly relaxes airway muscles to relieve symptoms, with an inhaled corticosteroid, which works to lessen underlying airway inflammation, thereby providing dual capabilities for immediate symptom relief alongside anti-inflammatory action. For instance, in January 2024, AstraZeneca, a UK–based biopharmaceutical company, released AIRSUPRA (albuterol/budesonide) in the US. This fixed-dose SABA-ICS rescue inhaler is designed to treat asthma symptoms and help avert sudden severe breathing difficulties, featuring its dual-component formulation delivered through pressurised metered-dose inhaler (pMDI) Aerosphere technology. AIRSUPRA improves acute symptom relief while simultaneously addressing airway inflammation, consequently reducing the risk of severe asthma exacerbations and enhancing overall asthma control.

Which Key Players Are Driving Competition In The Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market?

Major companies operating in the asthma and chronic obstructive pulmonary disease (copd) drugs market are Sun Pharmaceutical Industries Ltd., Viatris Inc., Hikma Pharmaceuticals PLC, Orion Corporation, Bausch Health Companies Inc., Kyorin Pharmaceutical Co. Ltd., Sandoz International GmbH, Mundipharma International Ltd., Ferrer Internacional S.A., Neopharm Group, Covis Pharma Group, Almirall S.A., Menarini Group, Cipla Health Ltd., Indoco Remedies Ltd., Intas Pharmaceuticals Ltd., Alembic Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd., Macleods Pharmaceuticals Ltd., Wockhardt Ltd., Ajanta Pharma Ltd., Emcure Pharmaceuticals Ltd., Abbott Laboratories, Endo International plc, Takeda Pharmaceutical Company Ltd.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/asthma-and-chronic-obstructive-pulmonary-disease-copd-drugs-global-market-report

Which Region Is Projected To Lead The Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market During The Forecast Period?

North America was the largest region in the asthma and COPD drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the asthma and chronic obstructive pulmonary disease (copd) drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24472&type=smp

Browse Through More Reports Similar to the Global Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market 2026, By The Business Research Company

Anti Asthmatics And Copd Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/anti-asthmatics-and-copd-drugs-global-market-report

Digital Dose Inhalers Market Report 2026

https://www.thebusinessresearchcompany.com/report/digital-dose-inhalers-global-market-report

Inhaled Antibiotics Market Report 2026

https://www.thebusinessresearchcompany.com/report/inhaled-antibiotics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info